News Quantified

IDXG – interpace biosciences inc (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Interpace Biosciences Announces Record Third Quarter 2024 Financial and Business Results

Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq

Form 8-K INTERPACE BIOSCIENCES, For: Nov 12

Form 10-Q INTERPACE BIOSCIENCES, For: Sep 30

Form 8-K INTERPACE BIOSCIENCES, For: Nov 04

Form SC 13D/A INTERPACE BIOSCIENCES, Filed by: 1315 Capital II, L.P.

Form SC 13D/A INTERPACE BIOSCIENCES, Filed by: Ampersand 2018 Limited Partnership

Top News Gainers

7/15 Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners 16.6%

1/16 Interpace Diagnostics Group Inc (NASDAQ: IDXG) had its price target raised by analysts at Oppenheimer Holdings Inc. from $2.00 to $17.00. They now have an "outperform" rating on the stock. 13.8%

7/19 Form 8-K Interpace Diagnostics For: Jul 15 13.8%

1/27 Form D INTERPACE BIOSCIENCES, 13.1%

4/15 Interpace Diagnostics Group Inc (NASDAQ: IDXG) is now covered by analysts at Janney Montgomery Scott. They set a "buy" rating on the stock. 12.7%

4/27 Interpace Biosciences Announces Contract with Lab Benefits Management Firm 11.4%

12/17 Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT® 10.3%

1/6 Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus 10.0%

1/7 Interpace Diagnostics Group Inc (NASDAQ: IDXG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock. 8.4%

4/6 Form 4 INTERPACE BIOSCIENCES, For: Mar 12 Filed by: STOVER JACK E 7.2%

Top News Decliners

4/22 Form 8-K INTERPACE BIOSCIENCES, For: Apr 22 -30.7%

8/13 Q2/2019 6/30/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -20.0%

3/11 Interpace Diagnostics Issues Update Regarding Announced Contract with BCBS of Massachusetts -19.7%

1/24 Form 4 INTERPACE BIOSCIENCES, For: Jan 22 Filed by: STOVER JACK E -18.6%

6/20 Interpace Diagnostics Announces Coverage of Molecular Thyroid Testing by Independence Blue Cross -17.1%

1/30 Interpace Biosciences Announces Addition to Board of Directors and Changes in Leadership -15.1%

7/31 Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan -13.0%

11/13 Q3/2019 9/30/2019 EPS -0.190 ZacksConsensus -0.090 ActVsEst (0.100) - Miss -12.8%

4/23 Interpace Diagnostics Group Inc (NASDAQ: IDXG) had its price target lowered by analysts at Alliance Global Partners from $21.00 to $9.25. They now have a "buy" rating on the stock. -12.3%

11/14 Form 8-K INTERPACE BIOSCIENCES, For: Nov 12 -12.0%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day